• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >Comparison of oral dydrogesterone and vaginal micronized progesterone for luteal phase support in intrauterine insemination
【24h】

Comparison of oral dydrogesterone and vaginal micronized progesterone for luteal phase support in intrauterine insemination

机译：口服染色体和阴道微粉化孕酮对宫内节制物中氯化物相载体的比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study aims to compare the pregnancy outcomes of vaginal micronized progesterone capsules with oral dydrogesterone in subjects with unexplained subfertility who are undergoing IUI in conjunction with ovarian stimulation by using rFSH. A total of 432 patients with unexplained subfertility who underwent IUI in conjunction with ovarian stimulation were enrolled in this retrospective study. Patients were randomized into two groups: (1) dydrogesterone or (2) vaginal micronized progesterone capsules, for luteal phase support. Clinical pregnancy and live birth were the primary outcome measures of the present study. Dydrogesterone was used in 233 participants (54%) and 337 cycles, while 199 participants (46%) and 233 cycles received vaginal micronized progesterone capsule treatment. The proportion of clinical pregnancies (7.4% vs. 10.2%, p = .213), live births (68% vs. 73%, p = .286) were similar in the two groups. Oral dydrogesterone and vaginal micronized progesterone provide similar pregnancy outcomes in terms of clinical pregnancy and live birth rates in women undergoing IUI in conjunction with ovarian stimulation with rFSH. Given the simple and easy administration, lack of safety concerns and better patient tolerability, we suggest that oral dydrogesterone might be preferred for luteal phase support in IUI.
机译：本研究旨在将阴道微粉化孕酮胶囊与口服莫迪辛酮的妊娠晚期与口服莫斯特酮与未解释的体育症进行比较，通过使用RFSH结合卵巢刺激正在进行IUI。在这项回顾性研究中，共有432名未解释的患有未解释的外部过度的过度的患者，涉及卵巢刺激。患者被随机分为两组：（1）莫德英酮或（2）阴道微粉化孕酮胶囊，用于耐肺相载体。临床妊娠和活产是本研究的主要结果措施。 Dydrogestone用于233名参与者（54％）和337个循环，而199名参与者（46％）和233个循环接受了阴道微粉化孕酮胶囊治疗。临床妊娠的比例（7.4％与10.2％，p = .213），活产（68％vs.73％，p = .286）在两组中相似。口服莫德英酮和阴道微粉化孕酮在临床妊娠和患有IUI妇女的活产率与RFSH结合的患者的活产率提供了类似的妊娠晚期。鉴于管理简单易行，缺乏安全性和更好的耐受性，我们建议口服莫迪斯酮可能是IUI中患者的患病症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号